Thyrocare Technologies Limited has released its investor presentation for the second quarter and half year ended September 30, 2026. The presentation details the company’s unaudited financial results, showcasing key performance metrics and operational highlights. It also outlines the company’s strategic direction and future growth pillars, offering a comprehensive view of its ongoing business performance and strategic initiatives for the upcoming periods.
Thyrocare Presents Q2 FY27 Unaudited Financial Results
Thyrocare Technologies Limited has officially shared its investor presentation for the quarter and half year ended September 30, 2026. This document serves as a detailed overview of the company’s unaudited financial performance for the period. The presentation was made available following an earnings conference call scheduled for October 29, 2026.
Key Highlights from the Presentation
The presentation covers critical aspects of Thyrocare’s business, including:
- Who We Are: An introduction to the company’s identity and operations.
- Our Journey: A look back at the company’s evolution and milestones.
- Q2 FY27 Key Performance Metrics: Detailed metrics showcasing operational efficiency and growth. This includes significant improvements in Lab Network, Active Franchisee numbers, and Test Menu offerings.
- Other Highlights of Q2 FY27: This section details strategic initiatives such as the launch of India’s first pregnancy kit with a lab test and the expansion of its laboratory network with 5 new labs launched during the quarter across various cities like Asansol, Nasik, Madurai, and Jabalpur. Strengthening relationships with channel partners and doctors through various meetings is also highlighted.
- Q2 FY27 Financial Performance: This section dives deep into the financial outcomes, presenting Consolidated revenue growth of +25% and Standalone revenue growth of +27%. EBITDA and PAT also saw substantial year-on-year growth at +25% and +26%, respectively. Financial statements for both standalone and consolidated entities, along with the balance sheet and cash flow statements, are included.
- Divestment Impact: The presentation also addresses the divestment of Nueclear Healthcare (NHL), detailing the sale consideration of INR 141.4 Cr and the resulting impact on Thyrocare’s financial statements, including impairments.
- Going Forward – Key Pillars of Growth: The company outlines its future strategy, focusing on strengthening its Franchise Network, building Institutional Partnerships, driving a Routine to Remarkable strategy with specialized offerings, and fostering Scientific Engagement.
The investor presentation is also accessible on the company’s official investor relations website: https://investor.thyrocare.com/.
Source: BSE
